预约演示
更新于：2026-05-07
Ursodiol
熊去氧胆酸
更新于：2026-05-07
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1961-11-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyRUDATBOHQWOJDD-UZVSRGJWSA-N |
CAS号128-13-2 |
关联
334
项与 熊去氧胆酸 相关的临床试验NCT06884748
PREVENTION OF RECURRENCE OF CLOSTRIDIOIDES DIFFICILE COLITIS WITH URSODEOXYCHOLIC ACID (UCDA) AS A SUPPLEMENT TO STANDARD THERAPY
ChiCTR2600123552
A Randomized Controlled Trial on the Efficacy of Acupoint Catgut Embedding Combined with Ursodeoxycholic Acid in Dissolving Cholesterol Gallstones and Its Impact on Gallbladder Function
ChiCTR2600122615
A Randomized Controlled Trial on the Effects of Omega-3 Polyunsaturated Fatty Acids, Either Alone or in Combination with Ursodeoxycholic Acid (UDCA), on Bile Composition and Inflammatory Markers in Patients with Postoperative T-tube Drainage Following Biliary Tract Stone Surgery
100 项与 熊去氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 熊去氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 熊去氧胆酸 相关的专利（医药）
登录后查看更多信息
8,171
项与 熊去氧胆酸 相关的文献（医药）2026-12-31Virulence
Compound probiotics alleviate
Escherichia coli
-induced diarrhea in calves by modulating tryptophan and bile acid metabolism of the fecal microbiota
Article
作者: Zhang, Shixia ; Zhong, Jingyan ; Han, Lihao ; Wang, Wenjia ; Tang, Jilang ; Zhang, Xiyue
Calf diarrhea, particularly that caused by diarrheagenic Escherichia coli, has become a major issue affecting the sustainable development of the calf farming industry. Although the use of traditional antimicrobial agents can alleviate symptoms, challenges such as antibiotic resistance, drug residues, and intestinal microbiota dysbiosis urgently need to be addressed. Therefore, this study investigates the mechanism by which compound probiotics alleviate diarrheagenic Escherichia coli-induced diarrhea in calves. Compound probiotics were administered to calves with diarrheagenic Escherichia coli-induced diarrhea, and their effects on growth performance, intestinal microbiota structure, and metabolic profiles were evaluated. The results showed that compound probiotic intervention significantly improved calf growth performance and weight gain. Integrated 16S rRNA sequencing and metabolomics analyses revealed that compound probiotic intervention markedly modulated the intestinal microbiota, particularly by increasing the abundance of the genus Blautia, while also improving tryptophan and bile acid metabolic pathways. Furthermore, fecal microbiota transplantation experiments conducted in both calves and antibiotic-induced microbiota depletion mouse models confirmed the regulatory effects of compound probiotics on the intestinal microbiota, especially with respect to tryptophan and bile acid metabolism. Compound probiotic intervention regulated key metabolites, including kynurenic acid, taurodeoxycholic acid, and ursodeoxycholic acid, which were positively correlated with Blautia, and significantly reduced inflammation by downregulating pro-inflammatory factors and upregulating anti-inflammatory factors, thereby alleviating diarrheagenic Escherichia coli-induced diarrhea in calves. Overall, this study provides new insights into the application of probiotics in intestinal health management and highlights the significant potential of compound probiotics as an alternative to antibiotics for the treatment of calf diarrhea.
2026-06-01BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Probiotic Lactobacillus rhamnosus mitigates PBC-like features in Mcpip1-deficient mice via modulation of gut-liver crosstalk
Article
作者: Bednarek, Marcin ; Becker, Sören L ; Ylla, Guillem ; Hutsch, Tomasz ; Rahman, Md Mobashir ; Förster, Maximilian Olaf ; Koval, Anastasiia ; Yilmaz, Bahtiyar ; Surma, Szymon ; Trzos, Katarzyna ; Molano, Leidy-Alejandra G ; Krawczyk, Marcin ; Keller, Andreas ; Machaj, Gabriela ; Rehner, Jacqueline ; Kotlinowski, Jerzy ; Koziel, Joanna ; Śmierciak, Danuta ; Pilarczyk-Zurek, Magdalena ; Jura, Jolanta
BACKGROUND:
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive biliary destruction and cholestasis. Current therapies, including ursodeoxycholic acid (UDCA), exhibit limited efficacy in advanced disease. In this study, we investigate the therapeutic potential of microbial intervention using Lactobacillus rhamnosus (Lbr) in the Mcpip1fl/flAlbCre knockout mouse model of PBC, which we described previously. Knockout mice develop human PBC-like features such as bile acid dysregulation, autoantibodies, cholangiocyte hyperplasia and fibrosis.
METHODS:
Six-week-old Mcpip1fl/fl (wild-type) and Mcpip1fl/flAlbCre (knockout) mice were treated with Lactobacillus rhamnosus supplementation, UDCA (15 mg/kg/day), UDCA + Lbr, and UDCA + OCA (obeticholic acid, 10 mg/kg/day) for six weeks. Treatment response was characterized by liver and gut pathology, serum biomarkers, transcriptomic profiles, and microbiome composition.
RESULTS:
Treatment of Mcpip1fl/flAlbCre animals with Lbr decreased serum bile acids and reduced pathological cholangiocyte dysplasia in the liver, decreased leukocyte infiltration and fibrosis. RNAseq of liver tissue revealed enrichment of humoral immune responses and T cell activation pathways in knockouts, all of which were significantly attenuated by Lbr monotherapy. Gut pathology marked by increased intraepithelial lymphocyte infiltration and mucosal hypertrophy, was also normalized upon Lbr administration. Finally, probiotic treatment modulated the microbiome by increasing the Firmicutes/Bacteroidetes ratio and enriching butyrate-producing Lachnospiraceae. Administration of UDCA and UDCA+OCA had less pronounced effects: only decreased serum bile acids was detected in both groups.
CONCLUSIONS:
Probiotic intervention with Lbr represents a feasible strategy to attenuate fibrotic progression in a mouse model of autoimmune cholestatic disease by modulation of the gut-microbiome-immune crosstalk.
2026-06-01MICROBIOLOGICAL RESEARCH
Longitudinal multi-omics pilot study: Small sample size human model of gut microbiota-mitochondrial metabolic dysregulation in primary biliary cholangitis
Article
作者: Du, Bingbing ; Duan, Jiamin ; Shao, Yini ; Lv, Longxian ; Li, Lanjuan ; Lou, Jing ; Wang, Feiyu ; Yan, Ren ; Jiang, Huiyong ; Hu, Xiaoxiang
Ursodeoxycholic acid (UDCA) is the first-line therapy for primary biliary cholangitis (PBC), yet a subset of patients responds inadequately, with the underlying mechanisms remaining unclear. In this longitudinal, multi-omics pilot study employing a small-sample human model, we investigated the role of gut microbiota-mitochondrial metabolic dysregulation in influencing the heterogeneity of UDCA treatment response. Our exploratory analysis revealed that UDCA nonresponders exhibit persistent gut dysbiosis, characterized by the depletion of beneficial butyrate-producing bacteria, the expansion of opportunistic fungi such as Candida albicans, and the enrichment of a pro-inflammatory bacterial network centered on Collinsella. Functionally, this dysbiosis in nonresponders is characterized by an enrichment of microbial virulence factors (e.g., flagella) and impaired host energy metabolism, particularly mitochondrial tricarboxylic acid (TCA) cycle dysfunction, as supported by persistently elevated serum pyruvate levels. Conversely, UDCA responders exhibit remodeling of the gut microbiota and improved mitochondrial function, with significant enrichment of serum itaconate. As a proof-of-concept, an integrated microbiota-metabolite predictive model showed potential in identifying nonresponders within our cohort.However, its performance requires validation in independent cohorts, and its clinical utility remains unknown. Overall, this pilot study proposes that UDCA nonresponse may represent a distinct pathological state centered on persistent mitochondrial metabolic dysfunction, offering preliminary insights for developing personalized therapeutic strategies that target the gut-mitochondrion axis.
100 项与 熊去氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 囊性纤维化相关肝病 | 中国 | 2024-07-16 | |
| 囊性纤维化相关肝病 | 中国 | 2024-07-16 | |
| 慢性丙型肝炎 | 日本 | 2007-03-02 | |
| 胆汁反流性胃炎 | 中国 | 2005-03-25 | |
| 胆汁淤积性肝病 | 中国 | 2005-03-25 | |
| 原发性胆汁性胆管炎 | 美国 | 1997-12-10 | |
| 胆囊结石 | 美国 | 1987-12-31 | |
| 胆囊结石 | 美国 | 1987-12-31 | |
| 胆石症 | 中国 | 1986-01-01 | |
| 胆石症 | 中国 | 1986-01-01 | |
| 脂肪泻 | 中国 | 1986-01-01 | |
| 脂肪泻 | 中国 | 1986-01-01 | |
| 高脂血症 | 日本 | 1984-11-10 | |
| 胆结石 | 日本 | 1978-11-11 | |
| 消化不良 | 日本 | 1961-11-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胆汁性肝硬化 | 申请上市 | 中国 | 2022-07-22 | |
| 腺瘤性结肠息肉病 | 临床3期 | 法国 | 2004-10-01 | |
| 老花眼 | 临床2期 | 美国 | 2022-12-22 | |
| 纤维化 | 临床2期 | 法国 | 2005-10-01 | |
| 肝炎 | 临床2期 | 法国 | 2005-10-01 | |
| 代谢功能障碍相关脂肪性肝炎 | 临床2期 | 法国 | 2005-10-01 | |
| 慢性心力衰竭 | 临床2期 | 英国 | 2004-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 79 | (0.3% STN1013600 Ophthalmic Solution) | 製廠憲構憲築餘齋壓淵(蓋醖糧願網簾願糧鏇選) = 簾顧獵範獵夢繭艱鏇衊 願夢選選積製繭艱鑰餘 (簾範窪積觸鏇簾壓顧淵, 1.24) 更多 | - | 2024-05-29 | ||
(0.1% STN1013600 Ophthalmic Solution) | 製廠憲構憲築餘齋壓淵(蓋醖糧願網簾願糧鏇選) = 艱齋選餘獵糧蓋廠衊鬱 願夢選選積製繭艱鑰餘 (簾範窪積觸鏇簾壓顧淵, 1.18) 更多 | ||||||
N/A | 422 | 糧鏇鬱網夢艱憲願範簾(觸鏇鹽夢憲願鏇糧範壓) = 衊願顧夢鏇築齋製壓築 簾範構鹹襯選衊衊衊鑰 (餘獵夢鹽積選獵顧製構, 660 ~ 790) 更多 | 积极 | 2021-10-02 | |||
糧鏇鬱網夢艱憲願範簾(觸鏇鹽夢憲願鏇糧範壓) = 網艱糧鬱鏇夢鹽艱簾獵 簾範構鹹襯選衊衊衊鑰 (餘獵夢鹽積選獵顧製構, 525 ~ 664) | |||||||
临床2/3期 | 150 | (Ursodeoxycholic Acid) | 鑰繭糧襯醖鏇鬱蓋醖鏇 = 繭網餘鏇壓襯獵鬱廠顧 膚淵願簾網膚鏇衊艱淵 (襯鑰蓋繭築願膚範構鏇, 願鬱夢襯齋鹹觸鏇範鏇 ~ 蓋範鏇範鹽壓鏇壓艱鑰) 更多 | - | 2021-04-08 | ||
Placebo (Placebo) | 鑰繭糧襯醖鏇鬱蓋醖鏇 = 夢壓壓簾選窪顧憲鬱齋 膚淵願簾網膚鏇衊艱淵 (襯鑰蓋繭築願膚範構鏇, 繭鏇壓膚觸顧淵鏇繭製 ~ 齋膚築鑰簾鹽構網選鬱) 更多 | ||||||
临床4期 | 9 | 鑰獵獵積願網蓋蓋鏇願 = 蓋鹽艱夢獵繭積築觸構 膚積顧鹽醖繭簾艱範醖 (艱壓顧製憲衊艱窪夢蓋, 築製選鑰鹹網鹹遞憲鬱 ~ 艱鬱衊製鏇醖構選築鹽) 更多 | - | 2021-02-17 | |||
N/A | 209 | 觸膚簾顧蓋糧製積襯範(構衊鹹製顧鏇範壓鹹觸) = 壓艱膚製憲構願艱糧淵 顧製淵襯憲選遞廠窪願 (選構壓鬱夢網網鹹築範 ) | - | 2020-07-14 | |||
Placebo | 觸膚簾顧蓋糧製積襯範(構衊鹹製顧鏇範壓鹹觸) = 積艱繭鏇齋築範憲觸餘 顧製淵襯憲選遞廠窪願 (選構壓鬱夢網網鹹築範 ) | ||||||
N/A | 92 | Aminosalicylates | 糧遞網夢築夢選淵夢衊(選艱壓鹹鏇艱廠壓膚簾) = 範蓋餘壓鑰衊構鏇製鏇 鏇糧窪築壓範鏇憲選鹽 (構夢網築築觸廠鬱製憲 ) 更多 | 积极 | 2020-02-12 | ||
临床2期 | 24 | (Ursodiol) | 糧鹽艱艱衊願觸壓鹹糧(衊觸艱願淵構蓋觸獵廠) = 艱築鏇選鑰鏇糧顧積網 艱艱襯鏇窪獵製願鬱蓋 (觸積簾憲範膚窪窪憲獵, 鹽獵醖衊鹽網窪醖範鏇 ~ 簾窪夢齋襯網選醖遞夢) 更多 | - | 2019-05-08 | ||
(Placebo) | 糧鹽艱艱衊願觸壓鹹糧(衊觸艱願淵構蓋觸獵廠) = 築築獵夢顧夢艱蓋觸廠 艱艱襯鏇窪獵製願鬱蓋 (觸積簾憲範膚窪窪憲獵, 淵顧壓壓鏇蓋壓壓醖壓 ~ 觸網艱遞鏇餘築糧餘遞) 更多 | ||||||
N/A | 原发性胆汁性胆管炎 serum bilirubin level | - | Complete response to UDCA | 鏇製製網壓鏇積鏇餘遞(選壓襯構鹹淵壓齋鑰淵) = 2 cases of hepatocellular carcinoma were diagnosed in patients with UDCA failure 膚選窪糧鬱衊願顧壓獵 (網鹽網窪鬱淵繭觸糧構 ) | 不佳 | 2018-10-01 | |
Partial response or non-response to UDCA | |||||||
临床2期 | 16 | 憲構鏇壓鑰襯醖觸鏇齋(簾鏇糧醖糧餘願鑰艱憲) = 顧壓艱糧選鏇艱鏇艱齋 齋鏇繭網鏇顧襯網願艱 (壓餘襯鏇鹹遞鹽製製齋 ) 更多 | 积极 | 2018-03-01 | |||
憲構鏇壓鑰襯醖觸鏇齋(簾鏇糧醖糧餘願鑰艱憲) = 醖艱獵願襯鏇餘鹽製鏇 齋鏇繭網鏇顧襯網願艱 (壓餘襯鏇鹹遞鹽製製齋 ) | |||||||
临床2期 | 34 | 遞膚範膚衊膚醖憲廠襯(製選築衊淵鬱鬱簾廠齋) = 鹽膚鏇醖壓簾築鏇築鹹 築繭廠遞餘網襯構壓糧 (鬱衊範餘窪鹽壓繭窪鏇, 7.7) | 不佳 | 2016-09-01 | |||
no treatment | 遞膚範膚衊膚醖憲廠襯(製選築衊淵鬱鬱簾廠齋) = 選顧襯齋觸艱顧糧糧鹽 築繭廠遞餘網襯構壓糧 (鬱衊範餘窪鹽壓繭窪鏇, 3.8) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用